PRME
Price
$2.96
Change
-$0.17 (-5.43%)
Updated
Feb 21 closing price
Capitalization
388.89M
11 days until earnings call
SONN
Price
$1.44
Change
+$0.01 (+0.70%)
Updated
Feb 21 closing price
Capitalization
4.41M
Ad is loading...

PRME vs SONN

Header iconPRME vs SONN Comparison
Open Charts PRME vs SONNBanner chart's image
Prime Medicine
Price$2.96
Change-$0.17 (-5.43%)
Volume$805.56K
Capitalization388.89M
Sonnet BioTherapeutics Holdings
Price$1.44
Change+$0.01 (+0.70%)
Volume$67.88K
Capitalization4.41M
PRME vs SONN Comparison Chart
Loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PRME vs. SONN commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PRME is a Hold and SONN is a Hold.

Ad is loading...
COMPARISON
Comparison
Feb 23, 2025
Stock price -- (PRME: $2.99 vs. SONN: $1.53)
Brand notoriety: PRME and SONN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PRME: 155% vs. SONN: 18%
Market capitalization -- PRME: $388.89M vs. SONN: $4.41M
PRME [@Biotechnology] is valued at $388.89M. SONN’s [@Biotechnology] market capitalization is $4.41M. The market cap for tickers in the [@Biotechnology] industry ranges from $393.7B to $0. The average market capitalization across the [@Biotechnology] industry is $2.43B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PRME’s FA Score shows that 0 FA rating(s) are green whileSONN’s FA Score has 1 green FA rating(s).

  • PRME’s FA Score: 0 green, 5 red.
  • SONN’s FA Score: 1 green, 4 red.
According to our system of comparison, SONN is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PRME’s TA Score shows that 5 TA indicator(s) are bullish while SONN’s TA Score has 2 bullish TA indicator(s).

  • PRME’s TA Score: 5 bullish, 3 bearish.
  • SONN’s TA Score: 2 bullish, 3 bearish.
According to our system of comparison, PRME is a better buy in the short-term than SONN.

Price Growth

PRME (@Biotechnology) experienced а +31.14% price change this week, while SONN (@Biotechnology) price change was -2.55% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.27%. For the same industry, the average monthly price growth was +3.99%, and the average quarterly price growth was +2.35%.

Reported Earning Dates

PRME is expected to report earnings on May 09, 2025.

SONN is expected to report earnings on Nov 29, 2023.

Industries' Descriptions

@Biotechnology (+4.27% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PRME($389M) has a higher market cap than SONN($4.42M). SONN YTD gains are higher at: 4.795 vs. PRME (2.397). SONN has higher annual earnings (EBITDA): -11.77M vs. PRME (-207.13M). PRME has more cash in the bank: 176M vs. SONN (149K). SONN has less debt than PRME: SONN (131K) vs PRME (41.2M). PRME has higher revenues than SONN: PRME (800K) vs SONN (18.6K).
PRMESONNPRME / SONN
Capitalization389M4.42M8,811%
EBITDA-207.13M-11.77M1,760%
Gain YTD2.3974.79550%
P/E RatioN/A0.29-
Revenue800K18.6K4,301%
Total Cash176M149K118,121%
Total Debt41.2M131K31,450%
FUNDAMENTALS RATINGS
PRME vs SONN: Fundamental Ratings
PRME
SONN
OUTLOOK RATING
1..100
7081
VALUATION
overvalued / fair valued / undervalued
1..100
71
Overvalued
24
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
100100
PRICE GROWTH RATING
1..100
6494
P/E GROWTH RATING
1..100
10096
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SONN's Valuation (24) in the null industry is somewhat better than the same rating for PRME (71). This means that SONN’s stock grew somewhat faster than PRME’s over the last 12 months.

SONN's Profit vs Risk Rating (100) in the null industry is in the same range as PRME (100). This means that SONN’s stock grew similarly to PRME’s over the last 12 months.

SONN's SMR Rating (100) in the null industry is in the same range as PRME (100). This means that SONN’s stock grew similarly to PRME’s over the last 12 months.

PRME's Price Growth Rating (64) in the null industry is in the same range as SONN (94). This means that PRME’s stock grew similarly to SONN’s over the last 12 months.

SONN's P/E Growth Rating (96) in the null industry is in the same range as PRME (100). This means that SONN’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PRMESONN
RSI
ODDS (%)
Bullish Trend 6 days ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 6 days ago
78%
Bullish Trend 6 days ago
78%
Momentum
ODDS (%)
Bullish Trend 6 days ago
83%
Bearish Trend 6 days ago
88%
MACD
ODDS (%)
Bullish Trend 6 days ago
86%
N/A
TrendWeek
ODDS (%)
Bullish Trend 6 days ago
81%
Bearish Trend 6 days ago
90%
TrendMonth
ODDS (%)
Bullish Trend 6 days ago
73%
Bullish Trend 6 days ago
73%
Advances
ODDS (%)
Bullish Trend 6 days ago
78%
Bullish Trend 19 days ago
80%
Declines
ODDS (%)
Bearish Trend 13 days ago
87%
Bearish Trend 17 days ago
90%
BollingerBands
ODDS (%)
N/A
Bearish Trend 6 days ago
90%
Aroon
ODDS (%)
Bearish Trend 6 days ago
90%
N/A
View a ticker or compare two or three
Ad is loading...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SONN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPY611.491.79
+0.29%
SPDR® S&P 500® ETF Trust
AAPL244.47-0.13
-0.05%
Apple
GME26.97-0.03
-0.11%
GameStop Corp
BTC.X95539.550000-233.835940
-0.24%
Bitcoin cryptocurrency
TSLA354.11-1.73
-0.49%
Tesla

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+5.28%
CRSP - PRME
64%
Loosely correlated
+5.03%
BEAM - PRME
59%
Loosely correlated
+3.36%
NTLA - PRME
57%
Loosely correlated
+7.76%
ALLO - PRME
54%
Loosely correlated
+39.22%
RXRX - PRME
53%
Loosely correlated
+1.04%
More

SONN and

Correlation & Price change

A.I.dvisor tells us that SONN and SNBIF have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SONN and SNBIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SONN
1D Price
Change %
SONN100%
-3.77%
SNBIF - SONN
28%
Poorly correlated
N/A
NTLA - SONN
27%
Poorly correlated
+7.76%
PRME - SONN
27%
Poorly correlated
+5.28%
CHRS - SONN
26%
Poorly correlated
-5.08%
ABCL - SONN
26%
Poorly correlated
+4.89%
More